Could Pfizer Become a Top Weight Loss Drug Stock? Don't Count on It.

The pharma's latest push to develop a weight loss pill isn't going well.On July 11, Pfizer (PFE 0.88%) made an announcement that came as a bit of a surprise to biopharma industry experts and Wall Street analysts alike. It's planning on advancing one of its early-stage weight loss programs into mid-stage trials. In due time, the move could make it a direct competitor to the weight loss market's tycoons, Novo Nordisk and Eli Lilly.Alas, shareholders are more likely to be left wanting than they are to experien ...